Profile data is unavailable for this security.
About the company
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company's segments include Pharmaceutical and Animal Health. Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells its human health vaccines primarily to physicians, wholesalers, distributors and government entities. Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
- Revenue in USD (TTM)63.92bn
- Net income in USD17.43bn
- Incorporated1970
- Employees75.00k
- LocationMerck & Co Inc126 East Lincoln Avenue,P.O. Box 2000RAHWAY 07065United StatesUSA
- Phone+1 (908) 740-4000
- Fax+1 (908) 423-1987
- Websitehttps://www.merck.com/
Mergers & acquisitions
| Acquired company | MRK:NYQ since announced | Transaction value |
|---|---|---|
| MoonLake Immunotherapeutics | 5.32% | -- |
| Modifi Biosciences Inc | -24.11% | 1.33bn |
| Unity Semiconductor Sas | -35.71% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | 11.10bn | -988.90m | 118.03bn | 6.10k | -- | 7.16 | -- | 10.63 | -3.88 | -3.88 | 42.86 | 64.20 | 0.4744 | 1.43 | 6.17 | 1,819,623.00 | -4.23 | 14.06 | -5.04 | 16.67 | 86.03 | 87.35 | -8.91 | 26.28 | 2.29 | -- | 0.0067 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| Gilead Sciences Inc | 28.74bn | 5.97bn | 139.01bn | 17.60k | 23.64 | 7.26 | 15.91 | 4.84 | 4.73 | 4.73 | 22.79 | 15.39 | 0.5098 | 3.45 | 6.35 | 1,632,671.00 | 10.58 | 5.26 | 13.63 | 6.38 | 78.29 | 78.47 | 20.76 | 12.54 | 1.23 | 7.80 | 0.5667 | 108.47 | 6.04 | 5.08 | -91.53 | -38.34 | -8.71 | 4.10 |
| Pfizer Inc | 62.46bn | 7.87bn | 144.29bn | 81.00k | 18.41 | 1.60 | 9.75 | 2.31 | 1.38 | 1.38 | 10.95 | 15.89 | 0.2911 | 1.46 | 5.47 | 771,148.10 | 3.68 | 7.45 | 4.49 | 9.43 | 74.57 | 69.10 | 12.64 | 20.37 | 0.9604 | 12.26 | 0.4066 | 64.22 | 6.84 | 9.10 | 275.82 | -5.27 | 2.32 | 3.13 |
| Amgen Inc | 34.13bn | 5.93bn | 160.37bn | 28.00k | 27.22 | 25.84 | 13.90 | 4.70 | 10.96 | 10.96 | 63.05 | 11.54 | 0.3743 | 1.59 | 4.58 | 1,218,786.00 | 6.51 | 8.43 | 8.50 | 10.66 | 64.07 | 72.81 | 17.39 | 21.90 | 0.878 | 7.06 | 0.9024 | 71.37 | 18.57 | 7.43 | -39.11 | -12.21 | 12.14 | 9.18 |
| Merck & Co Inc | 63.92bn | 17.43bn | 203.22bn | 75.00k | 11.78 | 4.21 | 9.19 | 3.18 | 6.87 | 6.87 | 25.19 | 19.21 | 0.5786 | 2.31 | 5.77 | 852,293.30 | 15.79 | 9.52 | 20.46 | 12.64 | 77.07 | 73.47 | 27.30 | 17.87 | 1.16 | 23.90 | 0.4186 | 72.96 | 6.74 | 10.40 | 4,589.59 | 24.64 | -0.5885 | 6.66 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 239.92m | 9.50% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 147.30m | 5.83% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 120.53m | 4.77% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 78.33m | 3.10% |
| Geode Capital Management LLCas of 31 Mar 2025 | 59.66m | 2.36% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2025 | 49.23m | 1.95% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 34.98m | 1.39% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2025 | 24.96m | 0.99% |
| BlackRock Investment Management (UK) Ltd.as of 31 Mar 2025 | 24.95m | 0.99% |
| Fisher Asset Management LLCas of 31 Mar 2025 | 24.45m | 0.97% |
